Proactive Investors - Run By Investors For Investors

SkinBioTherapeutics glowing after a positive 2018

It's been a great year for SkinBioTherapeutics PLC (LON:SBTX) with much of their critical R&D out of the way and the company now set to head into 2019 with a 'real commercial proposition' that's scalable for mass markets.
SkinBio's Cath O'Neill tells Proactive London about company innovations, the roadmap for 2019 and indeed how their presence at the recent Wellcome Genome Campus event upped their credibility within the scientific community. SkinBio has begun the third and final phase of a human study of its skin cream as it confirmed it remains in talks with potential commercial partners. A total of 120 people will take part in the trial, which is designed to test whether SkinBiotix retains the beneficial property to improve skin barrier health when in a cream formulation.

Meet Clinigen Group PLC, MaxCyte, Cello Health PLC, Oncimmune and Silence Therapeutics PLC at our event, London , 11 July 2019. Register here »
View full SBTX profile View Profile

SkinBioTherapeutics PLC Timeline

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use